Remember that NASA satellite photo of the Earth at super-high resolution? The space agency just posted the sequel, this time capturing the Northern Hemisphere at even higher clarity -- 121 megapixels.
Read the original:
Remember that NASA satellite photo of the Earth at super-high resolution? The space agency just posted the sequel, this time capturing the Northern Hemisphere at even higher clarity -- 121 megapixels.
Read the original:
NASA's Voyager 1 spacecraft has encountered a new environment more than 11 billion miles from Earth, suggesting that the venerable probe is on the cusp of leaving the solar system.
Read more here:
What unites the diverse group selected to participate in the inaugural ZeroTo510 medical device accelerator?
In a word, entrepreneurship.
That's the common thread that binds the founders of the six startups selected for the ZeroTo510 program in Memphis.
Photo by Mike Maple // Buy this photo
Ben Tempel (left) is CEO and Dr. Edward Chaum is a co-founder of Nanophthalmics, which is creating microscopic tools for ocular surgery.
Photo by Brandon Dill // Buy this photo
BioNanovations founders Charleson Bell (left) and Andre' Stevenson have developed TestQuick, a technology that uses "bio-nano" particles to reduce the time needed to determine the type of bacterial infection present in a sample.
Some are experienced health care professionals; some are just starting their careers. Some are full-fledged professors at prestigious universities; some are graduate students and research assistants. Some are Memphians; others live and work elsewhere.
"It's inspirational how the spirit of entrepreneurship brings them together," said Allan Daisley, director of innovation and entrepreneurship for Memphis Bioworks Foundation, the organization that houses and administers ZeroTo510.
Created as the first medical device accelerator program in the country, ZeroTo510 aims to create more jobs, boost the local economy and make Memphis a place for entrepreneurs. To participate in ZeroTo510, the startups have to be based here.
Here is the original post:
Six startup medical device firms compete in Memphis for fame and fortune
Learn how the Center for High-rate Nanomanufacturing is working to enable access to new innovative manufacturing tools for industry, innovators, entrepreneurs and students.Boston, MA (PRWEB) June 18, 2012 Dr. Ahmed Busnaina, Director of the National Science Foundation Center for High-rate Nanomanufactuurig [CHN], will present a webinar entitled, “The Democratization of Manufacturing”. The ...
Read the rest here:
Public release date: 15-Jun-2012 [ | E-mail | Share ]
Contact: John Wallace wallacej@vcu.edu 804-628-1550 Virginia Commonwealth University
Richmond, Va. (June 15, 2012) A multi-institutional research study has uncovered a new mechanism that may lead to unique treatments for lung cancer, one of the leading causes of death worldwide.
The study recently published in the journal Genes & Development was a collaboration between Sanford-Burnham Medical Research Institute, Virginia Commonwealth University (VCU) Massey Cancer Center and the VCU Institute of Molecular Medicine, the University of California, San Diego, the University of Minnesota and St. Jude Children's Research Hospital. The scientists discovered that the protein Bax Inhibitor-1 (BI-1) protects lung cancer cells and promotes tumor growth by regulating autophagy, a complex process initiated under stressful conditions that breaks down a cell's own components to provide nutrients needed for survival.
"Cancer cells are remarkably adaptive and depend on a variety of mechanisms to ensure their survival and continued growth when challenged by their environment," says John C. Reed, M.D., Ph.D., professor and CEO of Sanford-Burnham. "By reducing levels of BI-1, it appears we were able to modulate intracellular signals and starve lung cancer cells of the energy needed to carry out one of their most important survival mechanisms, autophagy."
The researchers showed that BI-1 appeared to be linked to levels of calcium, which aids in signal transduction. Suppressing BI-1 reduced calcium levels in the endoplasmic reticulum, the interconnected network of sacs and tubules that manufacture, process and transport a variety of compounds for use inside and outside of cells. Lowering BI-1 levels led to reduced mitochondrial activity, oxygen consumption and adenosine triphosphate (ATP) levels. ATP is often called the "molecular unit of currency" due to the important role it plays in transporting chemical energy needed for metabolism.
The researchers' laboratory findings were confirmed by animal models that showed BI-1 suppression reduced human lung cancer tumor growth.
"These studies are the first to show that BI-1 may play an important survival role in cells under circumstances where oxygen and nutrient deprivation are encountered, such as the conditions that arise in advanced tumors or when cells are stressed by chemotherapy treatments," says Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair in Cancer Research and program co-leader of Cancer Molecular Genetics at VCU Massey Cancer Center, chairman of VCU's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. "We are excited by our findings because they uncover a new pathway that may be an effective target for future therapies to treat advanced lung cancer."
Next, the scientists hope to apply their findings to screen for potential drugs that can reduce BI-1-mediated protective autophagy in cancer cells.
###
Read the original post:
Scientists discover mechanism that promotes lung cancer growth and survival
MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor. This second "State of the Union" address serves to provide shareholders with a perspective on the company, its evolution and future potential.
Mr. Spoor began the communication by stating, "Our company vision is clear, our financial position is sound, our promising product portfolio is on track and our company is led by a highly qualified team with significant and directly applicable experience in the successful development of radiopharmaceuticals. Our comprehensive technology platform was developed by scientists at the Massachusetts General Hospital and we are well positioned to capitalize on its superior technology."
"As we advance our business model, we recognize the importance of keeping shareholders informed, and it is with this intention that I present this to you today."
Our Business Outlook
FluoroPharma is looking to capitalize on the growth of PET in cardiac diagnostics. In development are three novel cardiac PET radiopharmaceuticals, two of which are in clinical-stage and have advanced to phase II clinical. The third candidate is in the pre-clinical, early development stage.
FluoroPharma's products are aimed at improving overall patient care via improved disease detection and could potentially provide greater diagnostic accuracy compared to currently employed nuclear imaging agents and modalities, increase the use of PET in cardiac imaging, and help reduce the number of unnecessary diagnostic and therapeutic procedures.
In the U.S., there are estimated to be more than 2 million PET imaging procedures done per year according to Biotech Systems -- although the vast majority of these scans are for the diagnosis of cancer. PET is becoming more established in the cardiac setting as several factors have led to a shift in favor of PET for the diagnosis of cardiac disease.
Roughly one-third of all Americans are estimated to have some form of cardiovascular disease, with approximately 13 million people suffering from coronary artery disease. Cardiovascular disease is the number one leading cause of death in the U.S., claiming almost one million lives per year. People with cardiovascular disease typically have an accumulation of plaque within the walls of the coronary arteries (i.e. - atherosclerosis) that supply the myocardium (heart muscle) with oxygen. Known as coronary artery disease (CAD), the condition is progressive and can result in severely reduced supply of blood to the heart (i.e. - myocardial ischemia or ischemic heart disease). Acute coronary syndrome (ACS) is a term used to describe symptoms of the disease, such as chest pain or a heart attack. As these symptoms may not be present until the disease has progressed to an advanced stage, barring a reliable diagnosis and appropriate intervention, CAD is often fatal. Cardiac imaging is used to diagnose CAD and to determine the presence and severity of ischemic heart disease and the related risk of suffering a heart attack. It is also used to help determine the most appropriate course of treatment.
Our Portfolio
FluoroPharma's initial focus is the development of innovative positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). The FluoroPharma team is advancing two products in clinical trials for the assessment of cardiac disease. These first in class novel diagnostic agents have been designed to rapidly target myocardial cells. Other products in the pipeline include imaging agents for detection of a bio-marker associated with Alzheimer's disease and imaging agents that could potentially be used for imaging specific cancers.
Follow this link:
FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication
17-06-2012 23:30 Gb match vs kiilgore and toracasso. like and sub! leave a comment!
View post:
18-06-2012 05:49 Mr. M. - Intro/Outro you're now in a Beatehash state of MIND Text: Mr. M. Instrumental: Fanas - You're now in a Beatehas state of mind /The Curious Musical Letter (2010) No copyright intended. In order to avoid copyright infringement, please, do not upload this song on your channel. Thank you! Recording session,mix/mastering @ Facebook fan page Reverbnation: Artworks:
Excerpt from:
Mr. M. - Intro/Outro you're now in a Beatehash state of MIND - Video
LONGMONT -- It probably isn't what comes to mind when you think "Robocop," but Longmont police are using more and more technology to enforce the laws, and officers said it is saving time and improving accuracy.
A license plate reader can read and cross-reference hundreds of license plates with crime databases in an hour.
A computer system can pull data from car computers from moments before a crash to help investigators reconstruct accidents.
Officers use laser GPS systems to diagram accident scenes and upload the information directly into computers as part of the accident investigation and reconstruction.
And a speed-detecting laser gun has a mounted camera that determines whether motorists are following too closely.
Longmont Police Traffic Sergeant Mike Bell said the tools are speeding up investigations and helping to keep officers on the streets by keeping them out of court for ticket challenges, especially in cases involving the camera. It records a car as it is clocked and shows its following distance from another vehicle. Bell said motorists have given up on challenging tickets once they saw the video.
"We're talking about cars that are following right on someone's rear bumper," he said. "Where the problem comes in is most people will say, 'Well, I wasn't speeding. I drive this way all the time.'"
Bell said the standard for following distance is at least two car lengths under 45 mph and three car lengths at speeds faster than 45 mph.
The technology takes out the doubt of an officer's observations by keeping a video record of the incident.
Bell also said that accident investigations are sped up by saving officers time mapping accident scenes. The laser measurements and GPS software are also sometimes used to map other scenes, such as a recent discovery of a transient man's body. He died of natural causes, the coroner ruled, but police initially treated the area as a possible crime scene and carefully
Read the original:
Once upon a time, the world was ecstatic to get 56Kbps dial-up Internet access. In real years that wasnt that long agoless than 15 years ago, but in technology years it may as well be prehistoric. Now Verizon is introducing 300Mbps broadband service, but it will cost you.
Verizon has moved beyond regular FiOS with new FiOS Quantum services that promise to blow the doors off the Internet. Verizon is offering FiOS Quantum packages: up to 300Mbps downloads with 65Mbps upload speeds.
Verizon FiOS Quantum delivers mind-blowing 300Mbps broadband speed.According to Verizon, at 300MBps you can download 10 songs (approximately 50MB) in only 1.4 seconds, or download a 5GB HD movie in just over two minutes. Compare that against the slow 15Mbps entry-level plan, which takes an estimated 26.7 seconds to download the same songs, or a painstaking 45 minutes to download the movie.
The upload aspect is becoming more and more important as well, though. In years gone by, the Internet was more or less a one-way street of data flowing from servers on the Internet to endpoint systems. There was little need for data to flow the other direction. However, social networking, and cloud-based data, music and photo services have changed that.
The 15Mbps FiOS plan has an upload speed of 5Mbps. Verizon claims that uploading 200 photos (an estimated 250MB) at that speed will take almost seven minutes. Using the 300Mbps FiOS Quantum with 65Mbps upload speed cuts that down to about 30 seconds.
Verizon FiOS, and the new FiOS Quantum plans are primarily residential. Most individuals can probably make do just fine with 15Mbps, or spend a little extra cash for the 50Mbps tier. Small and medium businesses (SMBs)might benefit from the blazing 300Mbps speeds, thoughthe more PCs or devices trying to share the connection, the more the additional bandwidth is necessary. SMBs will also appreciate the ability to upload large files and data for clients in a fraction of the time.
There are two downsides to the 300Mbps FiOS Quantum. The first is that Verizon FiOS isnt available in all areas, so you may not be able to get FiOS at all. The second is that the 300Mbps FiOS Quantum package is $210 per month ($205 if you agree to a two-year contract).
The 150Mbps FiOS Quantum service (with the same 65Mbps upload speed) may be more sensible in many cases. At $100 a month (or $95 on a two-year contract), it costs less than half of the top of the line service while still delivering more than adequate broadband speeds.
You can follow Tony on his Facebook page, his Google+ profile, or contact him by email at tony_bradley@pcworld.com. He also tweets as @TheTonyBradley.
Read more here:
More charges are anticipated for a man behind bars in Medicine Hat accused of being an accessory to murder of a young woman still missing.
Read the original post:
Friends of Medicine Hat woman presumed dead still holding out hope
MIAMI BEACH, FLA. Abass Alavi, MD, a professor of Radiology and director of research education in the Perelman School of Medicine at the University of Pennsylvania School of Medicine, was honored with the Benedict Cassen Prize during the Society of Nuclear Medicine's (SNM) 2012 Annual Meeting in Miami Beach, Fla. This honor is given every two years by the Education and Research Foundation for SNM to living scientists or physician/scientists whose work has led to a major advance in basic or clinical nuclear medicine science.
Alavi received the award for his contributions in the development of modern imaging techniques, including positron emission tomography, which the society's leaders called "revolutionary tools for conducting basic science research and improving patient care."
Trained in internal medicine, hematology and nuclear medicine, Alavi has conducted pioneering research in modern imaging techniques including PET, single-photon emission-computed tomography (SPECT), computed tomography (CT), and magnetic resonance imaging (MRI).
"I am very honored to be recognized by such a prestigious prize," Alavi said. "I would like to share this great honor with my mentors, students and collaborators, without whom I could not have achieved this distinction. Ever since I entered medical school, I have searched for a specialty that would combine hard core sciences with the practice of medicine, and I found this combination best represented in the field of molecular imaging."
Alavi earned his medical degree from the University of Tehran School of Medicine in 1964. He then traveled to the United States and completed residencies at the Albert Einstein Medical Center and the Veterans Administration Hospital, both in Philadelphia, as well as at Beth Israel Hospital in Boston. He completed fellowships in hematology and in nuclear medicine at the University of Pennsylvania.
During his career at the Penn Medicine, Alavi has been a prolific researcher, with his research activities supported primarily by the National Institutes of Health. He has published more than 900 scientific papers, more than 150 book chapters, editorials and reviews and 34 books, and he has served in editorial positions for many journals and currently is the consulting editor for PET Clinics and editor in chief of Current Molecular Imaging and Advances in Bioscience and Biotechnology. Alavi has also mentored more than 140 trainees in nuclear medicine, some of whom are leaders in the field internationally.
Alavi has received numerous awards and designations recognizing his outstanding contributions to the field of nuclear medicine, including the SNM Georg Charles de Hevesy Nuclear Pioneer Award and the Berson-Yalow Award, the Fred Joliot Visiting Professorship at Orsay, France, and the Vic Haughton Honorary Lecture from the American Society of Functional Neuroradiology. He has received honorary doctorate degrees from the University of Bologna, Italy, and the University of the Sciences in Philadelphia.
To read the full news release, visit the Society for Nuclear Medicine's web site.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
View original post here:
Penn Radiology Professor Receives 2012 Benedict Cassen Prize for Research in Nuclear Medicine
June 19, 2012 10:44 AM
Top Chinese Traditional Medicine Firm Bares Overseas Expansion
SINGAPORE, June 19 (Bernama) -- Traditional Chinese medicine leader Tong Ren Tang is aiming to double the number of its retail outlets overseas to 100 by the end of this year from about 50 last year, a senior executive of the firm said.
Ding Yongling, deputy general manager of the Beijing Tong Ren Tang Group and general manager of the group's Hong Kong-based operation, said that the company's expansion plans include tapping the market outside of the Chinese mainland for the next three years.
Quoting Ding, China's Xinhua news agency said the company, with a history of 343 years, will open not just new outlets for their products abroad but also museums that will showcase the best of traditional Chinese medicine. The company will also conduct lectures and seminars on Chinese traditional drugs.
The company hopes to diversify its investments and tap the capital market to boost its overseas operations, she said.
Tong Ren Tang now has 66 retail outlets in 16 countries around the world. Its first market outside the Chinese mainland was first opened in 1993 in Hong Kong.
On March 17 this year, the company opened its fifth joint venture store in Singapore, followed by its eighth wholly-owned outlet in Hong Kong. It opened its first store in the Middle East in Dubai late last year. Its stores in Australia are also doing good business, Ding said.
"We are aiming to put up 100 stores by the end of 2015. This would include tapping the markets in Europe, the United States, the Middle East and Japan," Ding said.
Tong Ren Tang, which has become synonymous with the best of traditional Chinese medicine in many parts of China, started in 1669 as a small clinic. It was later designated as the supplier of herbal medicines to the royal family of the Qing dynasty for over a century before the empire's collapse.
Continued here:
Top Chinese Traditional Medicine Firm Bares Overseas Expansion
BOSTON--(BUSINESS WIRE)--
Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products to the Cell Therapy community, announced today that chairman and CEO Jim Reid is moderating a panel discussion at the 2012 Bio International Convention on Wednesday, June 20, in Boston. Featuring leaders from the regenerative medicine space, the panel is titled Stem Cell Therapies Fact or Fiction, and will share the lessons learned to-date from Scottish, European and American perspectives on the path to successfulcommercialization of stem cell therapies.
Jim Reid, Sistemic CEO, commented, "Sistemic is very active in the CellTherapyarena and aremembersof Alliance for Advanced Therapies (AAT) and the Alliance for Regenerative Medicine (ARM). We see the ability to raise this topic at the leading world event, BIO 2012, as animportantstep on the path to commercialization of these products which will be transformational in healthcare, and bring hope and cures to many people around the globe."
More information on the panel at BIO 2012:
What: Panel Discussion Featuring Leaders in the Regenerative Medicine Space
When: Wednesday, June 20, 3:00PM EDT
Where: Boston Convention Center, Room 254A
Who: Leaders of the Regenerative Medicine space:
Panel objectives include evaluating lessons learned and best practice including from the Scotland Roadmap for the commercialization of stem cell therapies; identifying global (US and EU) examples of progress in stem cell therapy commercialization; and facilitating a debate on the need for a global, multi-disciplinary approach to successful commercialization of stem cell therapies.
About Sistemic Ltd
Read more:
Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention
WALTHAM, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Atherotech Diagnostics Lab (Atherotech) now offers galectin-3 testing services to its laboratory customers and physicians. To offer galectin-3 testing, Atherotech is using the BGM Galectin-3TM test, which was cleared by the U.S. Food and Drug Administration in November 2010, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Launch of galectin-3 testing by Atherotech represents further expansion of the availability of galectin-3 testing to practicing physicians in the United States.
About BG Medicine, Inc.
BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.atherotech.com.
Read more:
CHICAGO, June 18, 2012 (GLOBE NEWSWIRE) -- Malini Daniel, a medical student at the Stanford School of Medicine in Palo Alto, Calif., today became a member of the Board of Trustees of the American Medical Association (AMA), the nation's largest physician organization. Ms. Daniel was installed as a trustee at the AMA's Annual Meeting in Chicago.
"I am very honored to represent future physicians in this position on the AMA Board of Trustees," said Ms. Daniel. "As a medical student, I'm excited to share my experiences in the rapidly changing field of medicine and I look forward to working with the board to help shape the future of health care."
Ms. Daniel will complete her medical degree with a concentration in health services research and policy in 2013. She was elected by her fellow medical students to serve a one-year term on the AMA Board of Trustees.
Ms. Daniel is dedicated to supporting global health initiatives. She has done extensive policy work and research for various programs including the World Health Organization, Joint United Nations Program for HIV/AIDS and the National AIDS Control Organization for the government of India.
Malini Daniel graduated with honors in 2006 from Harvard University with a Bachelors of Arts degree in biology and international policy, later receiving a Masters of Science degree in global health science from Oxford University. She currently resides in Palo Alto.
Media Contact: Liz Magsig AMA Media Relations Office: (202) 789-7419 Newsroom: (312) 239-4991 elizabeth.magsig@ama-assn.org
About the American Medical Association (AMA) The American Medical Association helps doctors help patients by uniting physicians nationwide to work on the most important professional, public health and health policy issues. The nation's largest physician organization plays a leading role in shaping the future of medicine. For more information on the AMA, please visit http://www.ama-assn.org.
This information was brought to you by Cision http://www.cisionwire.com http://www.cisionwire.com/american-medical-association/r/medical-student-malini-daniel-elected-to-ama-board-of-trustees,c9274034
Excerpt from:
Medical Student Malini Daniel Elected to AMA Board of Trustees
It's not altogether surprising that Priyanka Arunkumar is pondering a future in medicine. After her graduation from Saratoga High School, Priyanka may well follow in the footsteps of her brother, Amit (class of 2007), and attend UC-Berkeley and then medical school at UCSF.
But Priyanka's career trajectory has possibly been set less by sibling admiration than her own experiences: In the past couple of years, she's spent a lot of time around doctors.
On a trip to Hawaii during the holidays in her junior year, Priyanka decided to take a surfing lesson. At one point another surfer aimed his board in her direction, cutting her off. She leapt from her own board, and with arms and legs flailing, Priyanka landed knee-first ... on the only piece of coral anywhere in the area.
In the first few minutes after making contact with the submerged flora, Priyanka was unaware of any major discomfort. "I thought I had a little cut, and that something was stuck on my leg," she recalls. "I looked down and realized that the coral had ripped out a big piece of flesh above my knee; I could see down to the bone."
The injured teen began screaming for Amit, who was surfing nearby. "He said, 'Priyanka, stop complaining,' " she says, now able to laugh about the incident. "Then he saw the blood and realized a piece of my leg was missing and that we needed to get to a doctor immediately."
The siblings flagged down a ride to a hospital, which luckily was
"After that, another nurse said I was ruining the carpet with my blood, and told me to sit in the hallway. That's where a doctor happened to find me. He said he would move his schedule back so he could take care of me right away."
Priyanka's gaping wound was cleaned out and stitched up. X-rays showed that bits of coral were still embedded in her leg; it would take 12 days or so for full healing. Two days later the site became infected, requiring additional invasive treatment. By the time the varsity tennis team member returned to school, she did so in the wheelchair that would be her source of transportation for nearly four months. Physical therapy followed to strengthen her injured right leg and help her relearn to walk.
Upon her return to school, Priyanka says she found a very sympathetic student body. "Everyone was pretty shocked to see me in the chair. I think the entire campus knew who I was at that point. They were all pretty nice about it, and helped push me when I needed help. Someone nicknamed me 'Shark Bait' because the scar on my leg looks like a shark bite."
Despite her medical mishap, Priyanka managed to complete her junior year with high marks. Her senior year began relatively uneventfully: While enjoying her role as a producer/editor on the Falcons' multimedia staff, Priyanka successfully juggled a full load of AP classes. The idea of ever missing a day of school was inconceivable.
More:
Medical exams more challenging than finals exams for graduate
The Cleveland Clinic's plans to join forces with Ohio University's Heritage College of Osteopathic Medicine is good news for both institutions, and should be a worthwhile step toward increasing the number of primary care physicians in Northeast Ohio.
The philosophical underpinnings of osteopathy -- treating the whole body rather than focusing on specific symptoms of illnesses -- lend themselves particularly well to practice in such primary care categories as family medicine, internal medicine and pediatrics.
And the need for primary care doctors is expected to become acute within a decade. Some trackers of medical trends say the nation eventually will have 45,000 fewer primary care doctors than it needs.
Plain Dealer editorials express the view of The Plain Dealer's editorial board -- the publisher, editor and editorial-writing staff. As is traditional, editorials are unsigned and intended to be seen as the voice of the newspaper.
Talk about the topic of this editorial in the comments below.
Send a letter to the editor, which will be considered for print publication.
Email general questions or comments about the editorial board to Elizabeth Sullivan, editor of the editorial page.
The medical school extension campus that OU and the Clinic are establishing at Southpointe Hospital in Warrensville Heights is expected to enroll its first 32-student class in 2015.
Maybe that sounds like a drop in a bucket and still 45,000 jobs shy of what the country will need, but the hope is that the experience and connections that the students develop in this region during medical school will make them more likely to stay and help keep Northeast Ohio from becoming one of those dreaded "underserved areas."
Benefits will accrue much sooner to city and state coffers, to the tune of more than $700,000 a year in additional tax revenues. Mayor Brad Sellers is understandably enthusiastic.
More here:
Medical school extension will help building up primary care in Greater Cleveland: editorial
Add yet another factor to the emotional politics behind the drive to strip Rutgers University of control over its Camden campus, politics described by one state senator as "the beginning of a new civil war": The personal. The rejection that the powerful Norcross family of South Jersey felt at the refusal of the universitys president to take over the new Cooper Medical School in Camden.
"Rutgers could have had the medical school some years ago," said State Sen. Donald Norcross (D-Camden), the prime sponsor of the bill that aims to "reorganize" higher education in the state but also results in the first real threat to the autonomy and structural integrity of Rutgers University in its 56-year history as it is called under the law, "The State University of New Jersey."
"For whatever reason, they decided not to," said Norcross, whose brother George is political boss of South Jersey.
Through the efforts of Senate President Steve Sweeney (D-Gloucester) and the demands of Gov. Chris Christie, the bill is racing through the Legislature without so much as a pause to think of its price tag. The other day, the five senators on the Senate Higher Education committee voted for the bill, although the three Democrats and two Republicans admitted like Donald Norcross did they had no clue how much money it would cost. Critics have put the price at a quarter-billion dollars, maybe more.
Donald Norcross blamed the Rutgers "bureaucracy" for rejecting Cooper Medical School, but that bureaucracy is headed at least until the end of the month by outgoing president Richard McCormick.
McCormick, despite the reluctance of his governing boards and the opposition of faculty and many students, has pushed hard for the part of the bill that permits the universitys takeover of the Central Jersey operations of the University of Medicine and Dentistry of New Jersey (UMDNJ) even at the price of losing the Camden campus. Rutgers briefly had a medical school until 1971 when the state took it over as part of UMDNJ; regaining it would be McCormicks legacy.
The bill, as written by Sweeney, adds another sweetener the Rutgers takeover of UMDNJs Newark assets, giving Rutgers two medical school campuses. That part of the bill led to the comment about "civil war" when state Sen. Ronald Rice (D-Essex) implored the committee to hold the bill.
But the unanswered question hanging over the legislative hearings and the entire proposal is this: If it is good state policy for New Jerseys state university to take over medical education in Newark and Piscataway, why not in Camden?
Donald Norcross, in an interview after he testified before the Senate Higher Education Committee, answered: "Why would we want to empower Rutgers to take over an asset of Rowan University?"
Rowan University, a former state teachers college whose biggest major is still teacher education, had agreed to take in the medical school after McCormick declined. "Rowan has done a good job," Norcross said.
Originally posted here:
Braun: Rutgers-Camden medical school situation is personal, as well as political
By MARY SHEDDEN | The Tampa Tribune Published: June 18, 2012 Updated: June 18, 2012 - 7:00 AM
A University of South Florida medical school program highlighting leadership, empathy and business wherewithal will nearly triple its number of students this fall.
In August, 48 first-year Morsani College of Medicine students will join the 18 original participants in SELECT. The program targets students with strong self-awareness and self-management skills, as well as those showing an enhanced empathy toward patients and community.
A warning for new students: The five extra hours a week of discussions and self-reflection about communication, healthcare systems and management are intense, said first-year SELECT veteran Chris Pothering.
But these opportunities to meet with healthcare executives and other leaders make the commitment worth it, he said.
"It's almost like you forget you're in medical school when you sit down and have these interactions with people who are professionals in communication or in leadership," said Pothering, 28.
SELECT, or Scholarly Excellence, Leadership Experiences and Collaborative Training, has been brewing within the college for years. Positive feedback from the inaugural group of students and faculty mentors led to its sudden growth, said Alicia Monroe, the college's vice dean for educational affairs.
Eventually, the college will admit 56 SELECT students a year, in addition to a core medical class of 120 students. It highlights the importance in training new doctors to care for patients beyond the physical symptoms, Monroe said.
"We always have to be mindful of tasks, but also how it affects others," she said.
SELECT students often don't fall within the traditional medical admissions profile. Some of the students have other professional experience. Others have spent time in the military.
Read the original: